MovDisordV3, PascalFrancis, Corpus, bibRecord, 001E55

Risk of cancer after the diagnosis of Parkinson's disease : A historical cohort study

Identifieur interne : 001E55 ( PascalFrancis/Corpus ); précédent : 001E54; suivant : 001E56

Risk of cancer after the diagnosis of Parkinson's disease : A historical cohort study

Auteurs : Alexis Elbaz ; Brett J. Peterson ; James H. Bower ; PING YANG ; Demetrius M. Maraganore ; Shannon K. Mcdonnell ; J. Eric Ahlskog ; Walter A. Rocca

Source :

Movement disorders [ 0885-3185 ] ; 2005.

RBID : Pascal:05-0363479

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Tumeur maligne, Parkinson maladie, Facteur risque, Diagnostic, Etude cohorte, Etiologie, Cancer peau.

English descriptors

KwdEn :
- Cohort study, Diagnosis, Etiology, Malignant tumor, Nervous system diseases, Parkinson disease, Risk factor, Skin cancer.

Abstract

We investigated the risk of cancer after the diagnosis of Parkinson's disease (PD) through a historical cohort study. We used the medical records-linkage system of the Rochester Epidemiology Project to identify all incident cases of PD in Olmsted County, Minnesota from 1976 through 1995. Patients with PD were matched by age (± 1 year) and gender to referent subjects from the same population. For 196 patients and 185 referent subjects, we ascertained the incidence of cancer through medical records abstraction between the date of diagnosis (or index date) and death, loss to follow-up, or end of study. The risk of cancer was higher among patients than in referent subjects (relative risk [RR] = 1.64; 95% confidence interval [CI] = 1.15-2.35; P = 0.007). The RR did not change noticeably after adjustment for smoking. The increased risk was significant for nonmelanoma skin cancer (RR = 1.76; 95% CI = 1.07-2.89; P = 0.03), but not for other more severe types of cancer; therefore, we cannot exclude the occurrence of a surveillance bias. Among PD patients, there was no relation between the risk of cancer and the cumulative dose of levodopa received or the use of other PD medications.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 20`
A06				`@2 6`
A08	`01`	`1`	`ENG`	`@1 Risk of cancer after the diagnosis of Parkinson's disease : A historical cohort study`
A11	`01`	`1`		`@1 ELBAZ (Alexis)`
A11	`02`	`1`		`@1 PETERSON (Brett J.)`
A11	`03`	`1`		`@1 BOWER (James H.)`
A11	`04`	`1`		`@1 PING YANG`
A11	`05`	`1`		`@1 MARAGANORE (Demetrius M.)`
A11	`06`	`1`		`@1 MCDONNELL (Shannon K.)`
A11	`07`	`1`		`@1 AHLSKOG (J. Eric)`
A11	`08`	`1`		`@1 ROCCA (Walter A.)`
A14	`01`			`@1 Departments of Health Sciences Research, Mayo Clinic College of Medicine @2 Rochester, Minnesota @3 USA @Z 1 aut. @Z 2 aut. @Z 4 aut. @Z 6 aut. @Z 8 aut.`
A14	`02`			`@1 Institut National de la Santé et de la Recherche Médicale Unit 708, Hôpital de la Salpêtrière @2 Paris @3 FRA @Z 1 aut.`
A14	`03`			`@1 Department of Neurology, Mayo Clinic College of Medicine @2 Rochester, Minnesota @3 USA @Z 3 aut. @Z 5 aut. @Z 7 aut. @Z 8 aut.`
A20				`@1 719-725`
A21				`@1 2005`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000138604660090`
A44				`@0 0000 @1 © 2005 INIST-CNRS. All rights reserved.`
A45				`@0 48 ref.`
A47	`01`	`1`		`@0 05-0363479`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 We investigated the risk of cancer after the diagnosis of Parkinson's disease (PD) through a historical cohort study. We used the medical records-linkage system of the Rochester Epidemiology Project to identify all incident cases of PD in Olmsted County, Minnesota from 1976 through 1995. Patients with PD were matched by age (± 1 year) and gender to referent subjects from the same population. For 196 patients and 185 referent subjects, we ascertained the incidence of cancer through medical records abstraction between the date of diagnosis (or index date) and death, loss to follow-up, or end of study. The risk of cancer was higher among patients than in referent subjects (relative risk [RR] = 1.64; 95% confidence interval [CI] = 1.15-2.35; P = 0.007). The RR did not change noticeably after adjustment for smoking. The increased risk was significant for nonmelanoma skin cancer (RR = 1.76; 95% CI = 1.07-2.89; P = 0.03), but not for other more severe types of cancer; therefore, we cannot exclude the occurrence of a surveillance bias. Among PD patients, there was no relation between the risk of cancer and the cumulative dose of levodopa received or the use of other PD medications.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C02	`03`	`X`		`@0 002B17A03`
C03	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 01`
C03	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 01`
C03	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Tumeur maligne @5 02`
C03	`02`	`X`	`ENG`	`@0 Malignant tumor @5 02`
C03	`02`	`X`	`SPA`	`@0 Tumor maligno @5 02`
C03	`03`	`X`	`FRE`	`@0 Parkinson maladie @5 03`
C03	`03`	`X`	`ENG`	`@0 Parkinson disease @5 03`
C03	`03`	`X`	`SPA`	`@0 Parkinson enfermedad @5 03`
C03	`04`	`X`	`FRE`	`@0 Facteur risque @5 09`
C03	`04`	`X`	`ENG`	`@0 Risk factor @5 09`
C03	`04`	`X`	`SPA`	`@0 Factor riesgo @5 09`
C03	`05`	`X`	`FRE`	`@0 Diagnostic @5 10`
C03	`05`	`X`	`ENG`	`@0 Diagnosis @5 10`
C03	`05`	`X`	`SPA`	`@0 Diagnóstico @5 10`
C03	`06`	`X`	`FRE`	`@0 Etude cohorte @5 11`
C03	`06`	`X`	`ENG`	`@0 Cohort study @5 11`
C03	`06`	`X`	`SPA`	`@0 Estudio cohorte @5 11`
C03	`07`	`X`	`FRE`	`@0 Etiologie @5 12`
C03	`07`	`X`	`ENG`	`@0 Etiology @5 12`
C03	`07`	`X`	`SPA`	`@0 Etiología @5 12`
C03	`08`	`X`	`FRE`	`@0 Cancer peau @4 CD @5 96`
C03	`08`	`X`	`ENG`	`@0 Skin cancer @4 CD @5 96`
C03	`08`	`X`	`SPA`	`@0 Cáncer piel @4 CD @5 96`
C07	`01`	`X`	`FRE`	`@0 Encéphale pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
C07	`05`	`X`	`FRE`	`@0 Peau pathologie @5 41`
C07	`05`	`X`	`ENG`	`@0 Skin disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Piel patología @5 41`
N21				`@1 255`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 05-0363479 INIST
ET :	Risk of cancer after the diagnosis of Parkinson's disease : A historical cohort study
AU :	ELBAZ (Alexis); PETERSON (Brett J.); BOWER (James H.); PING YANG; MARAGANORE (Demetrius M.); MCDONNELL (Shannon K.); AHLSKOG (J. Eric); ROCCA (Walter A.)
AF :	Departments of Health Sciences Research, Mayo Clinic College of Medicine/Rochester, Minnesota/Etats-Unis (1 aut., 2 aut., 4 aut., 6 aut., 8 aut.); Institut National de la Santé et de la Recherche Médicale Unit 708, Hôpital de la Salpêtrière/Paris/France (1 aut.); Department of Neurology, Mayo Clinic College of Medicine/Rochester, Minnesota/Etats-Unis (3 aut., 5 aut., 7 aut., 8 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2005; Vol. 20; No. 6; Pp. 719-725; Bibl. 48 ref.
LA :	Anglais
EA :	We investigated the risk of cancer after the diagnosis of Parkinson's disease (PD) through a historical cohort study. We used the medical records-linkage system of the Rochester Epidemiology Project to identify all incident cases of PD in Olmsted County, Minnesota from 1976 through 1995. Patients with PD were matched by age (± 1 year) and gender to referent subjects from the same population. For 196 patients and 185 referent subjects, we ascertained the incidence of cancer through medical records abstraction between the date of diagnosis (or index date) and death, loss to follow-up, or end of study. The risk of cancer was higher among patients than in referent subjects (relative risk [RR] = 1.64; 95% confidence interval [CI] = 1.15-2.35; P = 0.007). The RR did not change noticeably after adjustment for smoking. The increased risk was significant for nonmelanoma skin cancer (RR = 1.76; 95% CI = 1.07-2.89; P = 0.03), but not for other more severe types of cancer; therefore, we cannot exclude the occurrence of a surveillance bias. Among PD patients, there was no relation between the risk of cancer and the cumulative dose of levodopa received or the use of other PD medications.
CC :	002B17; 002B17G; 002B17A03
FD :	Système nerveux pathologie; Tumeur maligne; Parkinson maladie; Facteur risque; Diagnostic; Etude cohorte; Etiologie; Cancer peau
FG :	Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie; Peau pathologie
ED :	Nervous system diseases; Malignant tumor; Parkinson disease; Risk factor; Diagnosis; Cohort study; Etiology; Skin cancer
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Skin disease
SD :	Sistema nervioso patología; Tumor maligno; Parkinson enfermedad; Factor riesgo; Diagnóstico; Estudio cohorte; Etiología; Cáncer piel
LO :	INIST-20953.354000138604660090
ID :	05-0363479

Links to Exploration step

Pascal:05-0363479

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Risk of cancer after the diagnosis of Parkinson's disease : A historical cohort study</title>
<author><name sortKey="Elbaz, Alexis" sort="Elbaz, Alexis" uniqKey="Elbaz A" first="Alexis" last="Elbaz">Alexis Elbaz</name>
<affiliation><inist:fA14 i1="01"><s1>Departments of Health Sciences Research, Mayo Clinic College of Medicine</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Institut National de la Santé et de la Recherche Médicale Unit 708, Hôpital de la Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Peterson, Brett J" sort="Peterson, Brett J" uniqKey="Peterson B" first="Brett J." last="Peterson">Brett J. Peterson</name>
<affiliation><inist:fA14 i1="01"><s1>Departments of Health Sciences Research, Mayo Clinic College of Medicine</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bower, James H" sort="Bower, James H" uniqKey="Bower J" first="James H." last="Bower">James H. Bower</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Mayo Clinic College of Medicine</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ping Yang" sort="Ping Yang" uniqKey="Ping Yang" last="Ping Yang">PING YANG</name>
<affiliation><inist:fA14 i1="01"><s1>Departments of Health Sciences Research, Mayo Clinic College of Medicine</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Maraganore, Demetrius M" sort="Maraganore, Demetrius M" uniqKey="Maraganore D" first="Demetrius M." last="Maraganore">Demetrius M. Maraganore</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Mayo Clinic College of Medicine</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mcdonnell, Shannon K" sort="Mcdonnell, Shannon K" uniqKey="Mcdonnell S" first="Shannon K." last="Mcdonnell">Shannon K. Mcdonnell</name>
<affiliation><inist:fA14 i1="01"><s1>Departments of Health Sciences Research, Mayo Clinic College of Medicine</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ahlskog, J Eric" sort="Ahlskog, J Eric" uniqKey="Ahlskog J" first="J. Eric" last="Ahlskog">J. Eric Ahlskog</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Mayo Clinic College of Medicine</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rocca, Walter A" sort="Rocca, Walter A" uniqKey="Rocca W" first="Walter A." last="Rocca">Walter A. Rocca</name>
<affiliation><inist:fA14 i1="01"><s1>Departments of Health Sciences Research, Mayo Clinic College of Medicine</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Mayo Clinic College of Medicine</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0363479</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0363479 INIST</idno>
<idno type="RBID">Pascal:05-0363479</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001E55</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Risk of cancer after the diagnosis of Parkinson's disease : A historical cohort study</title>
<author><name sortKey="Elbaz, Alexis" sort="Elbaz, Alexis" uniqKey="Elbaz A" first="Alexis" last="Elbaz">Alexis Elbaz</name>
<affiliation><inist:fA14 i1="01"><s1>Departments of Health Sciences Research, Mayo Clinic College of Medicine</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Institut National de la Santé et de la Recherche Médicale Unit 708, Hôpital de la Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Peterson, Brett J" sort="Peterson, Brett J" uniqKey="Peterson B" first="Brett J." last="Peterson">Brett J. Peterson</name>
<affiliation><inist:fA14 i1="01"><s1>Departments of Health Sciences Research, Mayo Clinic College of Medicine</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bower, James H" sort="Bower, James H" uniqKey="Bower J" first="James H." last="Bower">James H. Bower</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Mayo Clinic College of Medicine</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ping Yang" sort="Ping Yang" uniqKey="Ping Yang" last="Ping Yang">PING YANG</name>
<affiliation><inist:fA14 i1="01"><s1>Departments of Health Sciences Research, Mayo Clinic College of Medicine</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Maraganore, Demetrius M" sort="Maraganore, Demetrius M" uniqKey="Maraganore D" first="Demetrius M." last="Maraganore">Demetrius M. Maraganore</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Mayo Clinic College of Medicine</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mcdonnell, Shannon K" sort="Mcdonnell, Shannon K" uniqKey="Mcdonnell S" first="Shannon K." last="Mcdonnell">Shannon K. Mcdonnell</name>
<affiliation><inist:fA14 i1="01"><s1>Departments of Health Sciences Research, Mayo Clinic College of Medicine</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ahlskog, J Eric" sort="Ahlskog, J Eric" uniqKey="Ahlskog J" first="J. Eric" last="Ahlskog">J. Eric Ahlskog</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Mayo Clinic College of Medicine</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rocca, Walter A" sort="Rocca, Walter A" uniqKey="Rocca W" first="Walter A." last="Rocca">Walter A. Rocca</name>
<affiliation><inist:fA14 i1="01"><s1>Departments of Health Sciences Research, Mayo Clinic College of Medicine</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Mayo Clinic College of Medicine</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cohort study</term>
<term>Diagnosis</term>
<term>Etiology</term>
<term>Malignant tumor</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Risk factor</term>
<term>Skin cancer</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Tumeur maligne</term>
<term>Parkinson maladie</term>
<term>Facteur risque</term>
<term>Diagnostic</term>
<term>Etude cohorte</term>
<term>Etiologie</term>
<term>Cancer peau</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We investigated the risk of cancer after the diagnosis of Parkinson's disease (PD) through a historical cohort study. We used the medical records-linkage system of the Rochester Epidemiology Project to identify all incident cases of PD in Olmsted County, Minnesota from 1976 through 1995. Patients with PD were matched by age (± 1 year) and gender to referent subjects from the same population. For 196 patients and 185 referent subjects, we ascertained the incidence of cancer through medical records abstraction between the date of diagnosis (or index date) and death, loss to follow-up, or end of study. The risk of cancer was higher among patients than in referent subjects (relative risk [RR] = 1.64; 95% confidence interval [CI] = 1.15-2.35; P = 0.007). The RR did not change noticeably after adjustment for smoking. The increased risk was significant for nonmelanoma skin cancer (RR = 1.76; 95% CI = 1.07-2.89; P = 0.03), but not for other more severe types of cancer; therefore, we cannot exclude the occurrence of a surveillance bias. Among PD patients, there was no relation between the risk of cancer and the cumulative dose of levodopa received or the use of other PD medications.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>20</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Risk of cancer after the diagnosis of Parkinson's disease : A historical cohort study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>ELBAZ (Alexis)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>PETERSON (Brett J.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BOWER (James H.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>PING YANG</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>MARAGANORE (Demetrius M.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>MCDONNELL (Shannon K.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>AHLSKOG (J. Eric)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>ROCCA (Walter A.)</s1>
</fA11>
<fA14 i1="01"><s1>Departments of Health Sciences Research, Mayo Clinic College of Medicine</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Institut National de la Santé et de la Recherche Médicale Unit 708, Hôpital de la Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Neurology, Mayo Clinic College of Medicine</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA20><s1>719-725</s1>
</fA20>
<fA21><s1>2005</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000138604660090</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>48 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>05-0363479</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>We investigated the risk of cancer after the diagnosis of Parkinson's disease (PD) through a historical cohort study. We used the medical records-linkage system of the Rochester Epidemiology Project to identify all incident cases of PD in Olmsted County, Minnesota from 1976 through 1995. Patients with PD were matched by age (± 1 year) and gender to referent subjects from the same population. For 196 patients and 185 referent subjects, we ascertained the incidence of cancer through medical records abstraction between the date of diagnosis (or index date) and death, loss to follow-up, or end of study. The risk of cancer was higher among patients than in referent subjects (relative risk [RR] = 1.64; 95% confidence interval [CI] = 1.15-2.35; P = 0.007). The RR did not change noticeably after adjustment for smoking. The increased risk was significant for nonmelanoma skin cancer (RR = 1.76; 95% CI = 1.07-2.89; P = 0.03), but not for other more severe types of cancer; therefore, we cannot exclude the occurrence of a surveillance bias. Among PD patients, there was no relation between the risk of cancer and the cumulative dose of levodopa received or the use of other PD medications.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17A03</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Facteur risque</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Risk factor</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Factor riesgo</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Diagnostic</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Diagnosis</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Diagnóstico</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Etude cohorte</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Cohort study</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Estudio cohorte</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Etiologie</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Etiology</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Etiología</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Cancer peau</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Skin cancer</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Cáncer piel</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Peau pathologie</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Skin disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Piel patología</s0>
<s5>41</s5>
</fC07>
<fN21><s1>255</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 05-0363479 INIST</NO>
<ET>Risk of cancer after the diagnosis of Parkinson's disease : A historical cohort study</ET>
<AU>ELBAZ (Alexis); PETERSON (Brett J.); BOWER (James H.); PING YANG; MARAGANORE (Demetrius M.); MCDONNELL (Shannon K.); AHLSKOG (J. Eric); ROCCA (Walter A.)</AU>
<AF>Departments of Health Sciences Research, Mayo Clinic College of Medicine/Rochester, Minnesota/Etats-Unis (1 aut., 2 aut., 4 aut., 6 aut., 8 aut.); Institut National de la Santé et de la Recherche Médicale Unit 708, Hôpital de la Salpêtrière/Paris/France (1 aut.); Department of Neurology, Mayo Clinic College of Medicine/Rochester, Minnesota/Etats-Unis (3 aut., 5 aut., 7 aut., 8 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2005; Vol. 20; No. 6; Pp. 719-725; Bibl. 48 ref.</SO>
<LA>Anglais</LA>
<EA>We investigated the risk of cancer after the diagnosis of Parkinson's disease (PD) through a historical cohort study. We used the medical records-linkage system of the Rochester Epidemiology Project to identify all incident cases of PD in Olmsted County, Minnesota from 1976 through 1995. Patients with PD were matched by age (± 1 year) and gender to referent subjects from the same population. For 196 patients and 185 referent subjects, we ascertained the incidence of cancer through medical records abstraction between the date of diagnosis (or index date) and death, loss to follow-up, or end of study. The risk of cancer was higher among patients than in referent subjects (relative risk [RR] = 1.64; 95% confidence interval [CI] = 1.15-2.35; P = 0.007). The RR did not change noticeably after adjustment for smoking. The increased risk was significant for nonmelanoma skin cancer (RR = 1.76; 95% CI = 1.07-2.89; P = 0.03), but not for other more severe types of cancer; therefore, we cannot exclude the occurrence of a surveillance bias. Among PD patients, there was no relation between the risk of cancer and the cumulative dose of levodopa received or the use of other PD medications.</EA>
<CC>002B17; 002B17G; 002B17A03</CC>
<FD>Système nerveux pathologie; Tumeur maligne; Parkinson maladie; Facteur risque; Diagnostic; Etude cohorte; Etiologie; Cancer peau</FD>
<FG>Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie; Peau pathologie</FG>
<ED>Nervous system diseases; Malignant tumor; Parkinson disease; Risk factor; Diagnosis; Cohort study; Etiology; Skin cancer</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Skin disease</EG>
<SD>Sistema nervioso patología; Tumor maligno; Parkinson enfermedad; Factor riesgo; Diagnóstico; Estudio cohorte; Etiología; Cáncer piel</SD>
<LO>INIST-20953.354000138604660090</LO>
<ID>05-0363479</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E55 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001E55 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:05-0363479
   |texte=   Risk of cancer after the diagnosis of Parkinson's disease : A historical cohort study
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Risk of cancer after the diagnosis of Parkinson's disease : A historical cohort study

Risk of cancer after the diagnosis of Parkinson's disease : A historical cohort study

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri